Evotec buys Central Glass Germany
Evotec has bought the German manufacturing operations of Japan’s Central Glass for a nominal €1. The deal is subject to customary closing conditions and is expected to close on 1 November. The business will be renamed Evotec Drug Substance (Germany).
The deal brings Evotec a cGMP-certified pharmaceutical manufacturing campus in Halle with about 5,000 m2 of floor space and some 60 employees. According to Evotec, this enhances its strategy of “pursuing integrated discovery and development of new medicines that matter”, notably in precision medicines and rare diseases. The firm added that it intends to “invest meaningfully” to make Halle a centre of excellence for rare disease drug substance manufacturing.
RELATED ARTICLES
Two CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
CatSci has opened a second oligonucleotides laboratory, which it will use “to introduce novel workflows for the rapid production of vast numbers of oligos at a scale optimised for rapid screening”.
Swedish-based CDMO Recipharm announced at CPHI that it is “expanding its pharmaceutical development capabilities through targeted investments and the integration of cutting-edge technologies”.
